Antigen-expressing eDC line
CATALOG NUMBER · CR-C54-1MD54.1
hTERT-expressing eDC line
A renewable human APC research tool expressing an hTERT fragment (aa 301–700) covering known HLA-A2.1- and HLA-A*24:02-restricted epitopes.
Overview
MD54.1 is an antigen-expressing eDC line designed for hTERT-related antigen presentation and T cell research. Its antigen construct, hTERT aa 301–700, covers known HLA-A2.1- and HLA-A*24:02-restricted epitopes, creating a defined starting configuration for testing an immune response.
Fragment coverage does not by itself establish processing, presentation or recognition of each covered epitope. These questions require peptide-specific and functional evidence in the relevant HLA setting.
All MD54 lines are typed HLA-A*02:01 / HLA-A*24:02. The series is therefore suitable for studying HLA-A*02:01- or HLA-A*24:02-restricted antigen presentation, and the MD54.1 fragment contains epitopes restricted by both alleles.
For drug target discovery, connect the APC configuration to an appropriate effector population and target cell model. HLA blockade, antigen controls and viability measurements help distinguish recognition from nonspecific changes in assay signals.
Technical specifications
| Attribute | Current information |
|---|---|
| Product name / catalog number | MD54.1 · hTERT-expressing eDC line · Cat. No. CR-C54-1 |
| Antigen construct | hTERT fragment (aa 301–700) covering known HLA-A2.1- and HLA-A*24:02-restricted epitopes; epitope list to be added |
| HLA typing | HLA-A*02:01 / HLA-A*24:02 |
| Cell system | Human eDC line in an antigen-expressing configuration |
| Format & quantity | To be specified for MD54.1 |
| Expression / presentation evidence | Antigen expression characterization and peptide-specific presentation evidence to be added |
| Quality documentation | Line identity, mycoplasma testing, microbiological testing and culture performance documentation to be added for the offered material |
| Recommended passage window | To be established from growth and functional characterization of the line |
Growth conditions & culture development
MD54.1 culture support is being developed as a growth factor cocktail. The formulation must be evaluated for cell recovery, viability, growth, antigen expression and APC function across the intended culture interval.
| Culture attribute | Development information |
|---|---|
| Basal medium reference | MD54 source line documentation lists RPMI 1640 with 10% FBS, or X-VIVO with 5% serum replacement. Final MD54.1 conditions remain to be confirmed. |
| Vessel & starting density | Source line reference: T25 flask; 0.5–1.5 × 106 cells/mL. These are development starting conditions, not a validated MD54.1 protocol. |
| Medium renewal | Source line reference: approximately 2–3 times per week; optimize for the chosen cocktail and cell density trajectory. |
| Proposed growth factor cocktail | IL-2-Fc4, IL-15SA-Fc4 and FLT3L-Fc4 are candidate components. Final composition, activity units, concentrations and feeding schedule are under development. |
| Growth pattern | Adherent growth is described for the MD54 source line family; assess morphology and recovery for the engineered MD54.1 configuration. |
| Handling & release documentation | Final instructions will define thawing, culture support, recovery, sampling and product-specific testing. |
No optimized cocktail recipe or performance specification is presented here. Source line culture details guide development and must be verified for the antigen-expressing product.
Data & Figures
Download original figureFigure 1 / Functional data
Testing antigen dependence and HLA restriction
In this hTERT research example, eDC-stimulated cytotoxic T lymphocytes were assessed against U2OS target cell models.
- Antigen control
- The upper panel compares U2OS-Luc and U2OS-Luc/TERT. The TERT-positive model is engineered to express HLA-A2.1 and TERT.
- HLA control
- The lower panel compares control antibody with HLA-A2.1 blockade against U2OS-Luc/TERT targets.
- Readout
- Percentage cytolysis across effector-to-target (E:T) ratios.
- Interpretation
- Higher cytolysis of the TERT-positive model and reduced cytolysis under HLA blockade are consistent with antigen-related, HLA-dependent activity. Confirm antigen and HLA status for both target variants before attributing the upper panel difference to antigen alone.

Original research data
Read phenotype and function together
This research study combines flow cytometry panels, cytokine readouts and target cell cytolysis. These measurements describe different parts of the response.
The cytolysis panel compares A549-Luc with A549-Luc/A2.1. A549 expresses endogenous hTERT; the target comparison therefore tests the added HLA context in this model.
A population phenotype alone does not establish antigen specificity. Interpret the target cell comparison together with the antigen and HLA controls shown in Figure 1.
Product documentation
| Document | Status |
|---|---|
| MD54.1 product information sheet | Content reserved |
| HLA typing and hTERT fragment specification | Content reserved |
| Culture & handling instructions | Under development |
| Characterization and quality report for the line | Content reserved |
Product documentation will distinguish configuration information from lot-specific testing. The research figures above are not an MD54.1 release certificate.
Publications
Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells
Wu L, Zhang H, Jiang Y, Gallo RC, Cheng H. 115(19):E4453–E4462. DOI: 10.1073/pnas.1800550115.
View publicationCytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity
Zhao C et al. 74:117. DOI: 10.1007/s00262-025-03971-y.
View publicationSelected publications provide scientific context. Consult the documentation for the specific eDC configuration when assessing product suitability.